U.S. Markets closed

TMS Associates of Pennsylvania First Facility in the State to Treat Obsessive-Compulsive Disorder (OCD) with Deep Transcranial Magnetic Stimulation (Deep TMS)

HAVERFORD, Pa., Nov. 27, 2018 (GLOBE NEWSWIRE) -- TMS Associates of Pennsylvania LLC, Haverford’s leading mental health provider specializing in mood disorders, announced today that it is now offering BrainsWay’s latest FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS) therapy to patients with Obsessive-Compulsive Disorder (OCD). The facility has been offering Deep TMS therapy for the treatment of depression since 2016. As the first medical device to be FDA cleared for OCD, Deep TMS can be effective for the many patients in need of relief.

“We have seen firsthand how much people with OCD can suffer without effective treatment, and Deep TMS can provide them with the relief they’ve been seeking,” said Deborah Kim, M.D., co-founder of TMS Associates of Pennsylvania. “We have seen very impressive response and remission rates when treating depression with Deep TMS. Bolstered by the effectiveness of the treatment for depression, we are confident that Deep TMS will help provide better outcomes for our patients with OCD.”

TMS Associates of Pennsylvania was co-founded by Dr. Kim and Susan Rushing, M.D., J.D., who use their respective specialties to treat patients with mood and anxiety disorders. Dr. Kim focuses her work on treating pregnant and postpartum women, in addition to women suffering from depression and anxiety. As a clinical and forensic psychiatrist, Dr. Rushing specializes in developing therapies for treatment-resistant OCD, engaging patients in medication management and therapy.

“As an illness where achieving remission is difficult with standard psychiatric medications, psychiatrist have been searching for an effective neuromodulation option to treat OCD,” said Dr. Rushing. “BrainsWay’s FDA cleared coil to treat OCD is the solution we have been waiting for. We are excited to provide this innovative treatment to our patients in need of relief.”

Deep TMS has no systemic side effects, allowing patients to continue with their daily activities immediately following treatment.

About BrainsWay
BrainsWay Ltd./ BrainsWay USA (BRIN.TA), is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013, and is now FDA cleared (De-Novo) for the treatment of Obsessive Compulsive Disorder (OCD). The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.

About TMS Associates of Pennsylvania
TMS Associates of Pennsylvania was founded by Dr. Susan Rushing and Dr. Deborah Kim in 2016. The practice specializes in mood disorders including: treatment refractory depression, anxiety disorders, post-traumatic stress disorder (PTSD), OCD, bipolar disorder, mood disorders during pregnancy and neuromodulation using TMS.

TMS Associates of Pennsylvania Media Contact:
Susan Rushing, M.D., J.D.
610-726-1020

BrainsWay Media Contact:
Nechama Feuerstein
BrainsWay@antennagroup.com
201-373-2228